Investment Rating - The report initiates coverage of Chuangxin Industries with a BUY rating and a target price (TP) of HK$32, representing a 28% upside from the current price of HK$25 [3][8]. Core Insights - Chuangxin Industries presents a unique growth opportunity in the aluminium sector, driven by capacity expansion in Saudi Arabia and a significant cost advantage due to low green energy costs in China [1]. - The ongoing development of wind and solar power sources is expected to further reduce electricity costs by 2026-2027, enhancing profitability [1]. - The tight supply in the aluminium market is anticipated to support higher aluminium prices, with a 1% increase in aluminium prices projected to boost Chuangxin's earnings by 2.5% in 2026 [1]. Financial Summary - Revenue is projected to grow from RMB 13,815 million in FY23A to RMB 20,091 million in FY27E, with a notable increase of 29.1% in FY26E [2]. - Adjusted net profit is expected to rise significantly from RMB 1,003.6 million in FY23A to RMB 4,819.4 million in FY27E, reflecting strong growth potential [2]. - The earnings per share (EPS) is forecasted to increase from RMB 0.67 in FY23A to RMB 2.32 in FY27E, indicating robust profitability growth [2]. Capacity Expansion - Chuangxin currently operates 788 kt of electrolytic aluminium capacity in China and is expanding with a 500 kt project in Saudi Arabia, expected to be completed by Q2 2027 [7][14][16]. - The company has a high self-sufficiency rate for electricity, with plans to achieve over 50% of its power supply from green energy by 2027, significantly reducing costs [25][34][37]. Cost Structure - The current electricity cost for Chuangxin is RMB 0.33/kWh, lower than the industry average of RMB 0.40/kWh, with expectations to reduce this further to below RMB 0.20/kWh through green energy initiatives [25][37]. - The company’s captive coal-fired power plants provide 100% electricity self-sufficiency for aluminium smelting, enhancing its cost leadership in the sector [24][25]. Market Position - Chuangxin is positioned as a significant player in the aluminium market, being the 12th largest electrolytic aluminium producer in China as of 2024 [7]. - The company has established a strong customer base, with a significant portion of its revenue derived from major clients in the non-ferrous metal processing sector [39][41].

Report Summary 1. Report Industry Investment Rating - Not provided in the given content. 2. Core Viewpoints - The Macau gaming industry showed a solid start in 2026 with a 24% year-on-year growth in January's GGR, reaching 90.7% of the January 2019 level. The 2026 GGR target of MOP236bn seems conservative based on the 2025 growth momentum [7][10][11]. - In the fixed - income market, there were various price movements across different sectors such as Chinese/HK higher - yielding space, Chinese properties, SE Asian space, etc. Some bonds tightened while others widened or declined in price [2]. - Chinese IG KUAISH/MEITUA recovered and tightened 1 - 3bps in the morning [3]. 3. Summary by Directory Trading Desk Comments - In the FRN space, there were balanced two - way flows across AU/JP financial names, MAYMK, 2 - 3yr Korean quasi - sovereign issues, and HYNMTR, with the latter closing 1 - 2bps tighter. Front - end to belly Chinese AMC papers, POE/TMTs, and belly financial papers saw initial selling, widening spreads by 1 - 3bps, but spreads largely closed unchanged. TW lifers widened 3 - 5bps, and the Macau gaming complex had a range of - 0.2pt to + 0.1pt change. In Chinese/HK higher - yielding space, WESCHI 26 rose 1.4pts and WESCHI 28 edged 0.2pt higher, while EHICAR 26 - 27 dropped 0.7 - 2.3pts. In Chinese properties, VNKRLE 27 - 29 were 0.9 - 1.7pts lower. In SE Asian space, VLLPM 27 - 29 dived 7.6 - 9.6pts [2]. - In the morning, Chinese IG KUAISH/MEITUA recovered and tightened 1 - 3bps. RMs were buying perps, and PBs were switching out of short - dated to call EU AT1s. ACPM 4.85 Perp/FAEACO 12.814 Perp were 0.7 - 0.9pt lower, and NWDEVL 27 - 28 recovered 0.5 - 0.6pt [3]. Macro News Recap - On Monday, S&P (+0.54%), Dow (+1.05%), and Nasdaq (+0.56%) were higher. The S&P Global Manufacturing January 2026 PMI was 52.4 (higher than the expected 51.9), ISM Manufacturing January 2026 Prices was 59.0 (lower than the expected 59.3), and ISM Manufacturing January 2026 PMI was 52.6 (higher than the expected 48.5). The UST yield was higher, with 2/5/10/30 - year yields at 3.57%/3.83%/4.29%/4.90% [6]. Desk Analyst Comments - Macau's gross gaming revenue (GGR) in January 2026 increased 24.0% year - on - year to MOP22.6bn, representing 90.7% of the January 2019 GGR and being the highest January figure since 2019. The 2026 GGR target of MOP236bn seems conservative as GGR in 2025 increased 9.1% to MOP247.4bn, exceeding the revised forecast of MOP228bn. The 2026 forecast represents a 3.5% year - on - year growth from the 2025 revised GGR forecast. In 2025, Macau's tourist arrival was 40.1mn, a 15% year - on - year increase and exceeding the 2019 record [7][10][11]. - Macau gaming bonds are considered lower - beta and good carry plays. Top picks are MPELs and STCITYs, and WYNMAC'27 and '29 are yield pick - up plays. The report is neutral on MGMCHIs, SANLTDs, and SJMHOLs [13]. Offshore Asia New Issues - Priced: CMBC International Funding (HK) issued USD300mn with a 3 - year tenor at SOFR + 60, rated - / - /BBB - [17]. - Pipeline: No offshore Asia new issues pipeline on this day [18]. News and Market Color - There were 89 credit bonds issued onshore yesterday with an amount of RMB88bn. No credit bonds were issued on 2 Feb 2025 due to the Chinese New Year holiday. Trump said he would roll back 25% punitive tariffs and cut the levy on Indian goods to 18% from 25% in return for India stopping buying Russian oil. China's local government debt increased 15% in 2025 and remains manageable. Indonesia's coal exports declined 19.7% last year to USD24.5bn due to falling global prices. Huatai Securities raised USD698.6mn by selling HKD and RMB - denominated guaranteed bonds due 2028. UPL Limited 9MFY26 EBITDA rose 22% year - on - year to INR59.1bn (cUSD648mn) [19][20].

Market Overview - Global markets experienced significant fluctuations, with the Hang Seng Index closing at 26,776, down 2.23% for the day but up 4.47% year-to-date [1] - The US markets showed a contrasting trend, with the Dow Jones increasing by 1.05% and the S&P 500 by 0.54% [1] - Asian markets faced a sell-off in commodities, with gold prices dropping below $4,400 and silver falling over 15% [3] Industry Insights - The heavy truck industry in China saw a 39% year-on-year increase in sales in January, attributed to a low base from the previous year and manufacturers meeting sales targets ahead of schedule [4] - The outlook for heavy truck demand remains optimistic, with expectations of maintaining over 1.1 million units in 2026, driven by a replacement cycle and continued government subsidies [4] Company Analysis - Gako's (1167 HK) focus on KRAS-targeted therapies positions it as a leader in the field, with a robust product pipeline and a partnership with AstraZeneca to accelerate development [4][5] - Gako's core product, JAB-23E73, is expected to achieve peak sales of $1.9 billion, highlighting its significant market potential [7] - The company has developed innovative platforms for antibody-drug conjugates (ADCs), which are anticipated to enhance treatment efficacy and safety [6] Financial Projections - Gako's target price is set at HKD 10.34, based on a discounted cash flow model, reflecting its strong growth potential in the KRAS market [7] - Mindray (425 HK) is projected to see stable growth driven by its battery box and robotics businesses, with revenue forecasts for the second half of 2025 adjusted upward by 1% to HKD 137 billion [8] - The company is expected to maintain a gross margin of 29.1% despite rising raw material costs, indicating effective cost management strategies [8] Strategic Partnerships - Stone Pharmaceutical (1093 HK) has entered a significant partnership with AstraZeneca, valued at over $18.5 billion, to advance multiple projects in weight management and diabetes [9][10] - This collaboration not only enhances Stone's pipeline but also validates its AI-driven drug discovery capabilities [9]

Investment Rating - The report maintains a BUY rating for Minth Group, indicating a potential return of over 15% over the next 12 months [1][8]. Core Insights - The company is expected to see solid earnings growth in the second half of 2025, with a projected net profit increase of 17% year-over-year for FY25E. This growth is anticipated to accelerate further in FY26-27E, driven by the expansion in battery housing and contributions from new business segments such as humanoid robots and AI server liquid cooling systems [1][8]. - Revenue forecasts for FY25E, FY26E, and FY27E have been revised upwards by 3-6%, reflecting a positive outlook for the company's performance in these years [8][10]. Financial Summary - For FY25E, revenue is projected at RMB 25,945 million, with a year-over-year growth of 12.1%. Net profit is expected to reach RMB 2,708 million, reflecting a 16.8% increase [2][12]. - The company’s earnings per share (EPS) for FY25E is estimated at RMB 2.36, with a price-to-earnings (P/E) ratio of 13.5x [2][12]. - The gross profit margin is expected to be 28.7% for FY25E, with operating and net margins projected at 12.1% and 10.4%, respectively [10][12]. Share Performance - The target price for Minth Group has been set at HK$42.00, representing a 17.3% upside from the current price of HK$35.80 [3]. - The market capitalization of the company is approximately HK$42,313.8 million, with an average turnover of HK$228.4 million over the past three months [3]. Shareholding Structure - The largest shareholder is Chin Jong-Hwa's family, holding 38.1% of the shares, followed by Invesco Asset Management with 6.0% [4]. Growth Projections - The company anticipates a 16% year-over-year increase in NEV sales volume in Europe for FY26E, which is expected to benefit its battery housing business significantly [8]. - New business segments are projected to contribute over RMB 1 billion in revenue by FY27E, with additional contributions from door sealing systems and other new businesses expected to exceed RMB 0.5 billion [8]. Valuation - The report maintains a target price based on a P/E ratio of 13x for the revised FY26E EPS, reflecting confidence in the company's growth trajectory [8].

Investment Rating - The report maintains a "Buy" rating for CSPC Pharmaceutical Group with a target price of HK$13.93, up from the previous target of HK$11.05, indicating a potential upside of 45.1% from the current price of HK$9.60 [6][9]. Core Insights - A significant licensing agreement valued at over US$18.5 billion has been established with AstraZeneca, focusing on eight weight management and type II diabetes projects, which is expected to drive long-term growth for CSPC [3]. - CSPC has demonstrated a strong track record in business development, signing six licensing agreements since the end of 2024, which validates its drug discovery capabilities and suggests sustainable revenue streams in the medium to long term [4]. - The company reported total revenue of RMB 19.9 billion for the first nine months of 2025, with a core revenue decline of 19% year-on-year, although a recovery was noted in Q3 2025 with a 4.2% quarter-on-quarter increase in core revenue [5]. Financial Summary - For FY25E, CSPC's revenue is projected to be RMB 26.949 billion, reflecting a year-on-year decline of 7.1%, with a net profit of RMB 4.945 billion, which is expected to grow by 14.0% in FY26E [8][19]. - The company’s R&D expenses increased by 7.9% year-on-year to RMB 4.2 billion for the first nine months of 2025, representing a R&D expense ratio of 21.0% [5]. - The sales expense ratio decreased significantly from 29.2% in the first nine months of 2024 to 24.1% in the same period of 2025, indicating improved cost management [5]. Valuation Metrics - The report projects an increase in earnings forecasts due to the AstraZeneca deal, adjusting the DCF-based target price to HK$13.93, with a WACC of 9.34% and a terminal growth rate of 3.0% [6][16]. - The estimated EPS for FY25E is RMB 0.43, with a PE ratio of 20.1, which is expected to decrease to 14.9 by FY26E [8][19].

1. Report Industry Investment Rating - No specific industry investment rating is provided in the report 2. Core Viewpoints - The report analyzes the fixed - income market, including bond price movements, new issuances, and macro - economic factors. It also provides insights into the China economy based on PMI data and anticipates policy stimulus and GDP growth trends [2][3][13] - West China Cement's tender offer and new bond issuance are considered to lower its near - term refinancing risk, and the report maintains a buy rating on WESCHI 9.9 12/04/28 [7][8] 3. Summary by Relevant Catalogs Trading Desk Comments - Last Friday, financial FRNs traded 1bp wider. In HK, NWDEVL/VDNWDL complex surged 0.5 - 3.0pts. FAEACO 12.814 Perp rose 1.5pts. SHUION 26 - 29 edged 0.2 - 0.6pt higher. SUNHKC 26 was 0.1pt lower and SUNHKC 29 was 0.3pt higher. TW lifers were 2 - 4bps wider. Long - end MEITUA/KUAISH widened 2 - 3bps. EHICAR 26 was down by 0.6pt. WESCHI 26 - 28 were 0.1pt higher. In Chinese properties, VNKRLEs rose 1.8 - 2.7pts. FUTLAN 28 edged 1.1pts higher. LNGFOR 27 - 32 were 0.2pt lower to 0.2pt higher. In SE Asian space, OCBCSP/UOBSP traded 1 - 2bps wider. IHFLIN 27 - 30/TOPTB 6.1 Perp were unchanged to 0.1pt lower. VLLPM 27 - 29 rose 1.0 - 1.3pts. GLPSP Perps were up by 0.5 - 0.9pt. JP insurance subs like RESLIF 6.875 Perp leaked by 0.1pt. NTT 35/MUFG35 - 36 were 1 - 3bps wider. Yankee AT1s were 0.3pt weaker. In the Middle East, ARAMCO 30 - 56s/SECO 29 - 36s widened 1 - 4bps. Long - end KSAs were down 0.1 - 0.5pt. LGFV space was stable [2] - This morning, HYNMTR FRNs were 1 - 2bps tighter. KUAISH slightly recovered to 1bp tighter. ZHOSHK 28 spread was unchanged. FAEACO 12.814 Perp/VNKRLE 27 were 1.0 - 1.2pts lower. NDPAPE 14 Perp was 0.3pt higher. WESCHI 26 - 28 were 0.4 - 1.0pt higher [3] Marco News Recap - Last Friday, S&P (- 0.43%), Dow (- 0.36%) and Nasdaq (- 0.94%) were lower. Trump nominated Kevin Warsh to lead Federal Reserve. US Dec'25 PPI was +0.5% mom, higher than the market expectation of +0.2%. 2/5 - year UST yield was higher while 10/30 - year UST yield was lower. 2/5/10/30 - year yield was at 3.52%/3.79%/4.26%/4.87% [6] Desk Analyst Comments - West China Cement (Weschi) launched a tender offer for its USD200mn WESCHI 4.95 07/08/26 at a tender price of 101.238, equivalent to the bond's call price. The offer expires on 6 Feb'26 5pm CET. Weschi plans to redeem WESCHI 26 in full on 6 Mar'26 at 101.238 [7] - Concurrently, Weschi will issue USD300mn WESCHI 10.5 11/11/29 (-/B/B). Net proceeds will be used to refinance existing debts, including funding the tender offer and early redemption for WESCHI 4.95 07/08/26. The report maintains a buy on WESCHI 9.9 12/04/28 for its good carry, with WESCHI 28 trading at YTM of 9.8% at 100.3, up c2pts YTD. Weschi's earnings improved in 1H25, and near - term refinancing risk is viewed as lower [8] China Economy - China's manufacturing PMI retreated in January after a December rebound. Demand softened as new orders slipped back into contraction and export orders weakened again. Deflation pressure continued to ease, with raw material purchase and ex - factory prices both expanding, indicating PPI may return to positive sooner. Service PMI remained in contraction while construction PMI fell back, signaling pressure to stabilize fixed asset investment. Policy stimulus around CNY is expected, including stabilizing the property market and stimulating consumption. A 50bp cut in RRR and a 10bp cut in LPR in 1Q26 are expected, followed by an additional 10bp LPR cut in 3Q26. The broad fiscal deficit should remain almost flat at 8.5% in 2026, and the full - year GDP growth rate may decline from 5% in 2025 to 4.6% in 2026 [12][13] - Manufacturing PMI fell to 49.3% in January from 50.1% in December, with new order index declining to 49.2% from 50.8% and new export orders falling to 47.8% from 49.0%. Production eased but stayed in expansion at 50.6% in Jan. Deflation pressure continued to ease as raw material purchase prices stayed elevated and ex - factory prices improved. Import demand stayed weak, and inventory indicators remained subdued [14] - Non - manufacturing PMI softened in January. Service PMI edged down to 49.5% from 49.7%, with activity expectations improving. Service selling prices improved, while employment remained subdued. Construction fell to 48.8% in January, with new orders weakening and business expectations easing, indicating pressure on fixed asset investment [15] Offshore Asia New Issues Priced | Issuer/Guarantor | Size (USD mn) | Tenor | Coupon | Priced | Issue Rating (M/S/F) | | --- | --- | --- | --- | --- | --- | | ADM Elektrik | 500 | 5NC2 | 9.5% | 9.5% | B2/-/BB | | Tsetsen Mining and Energy | 300 | 5yr | 11.375% | 11.5% | Unrated | | West China Cement | 300 | 3.75yr | 10.5% | 10.5% | -/B/B | [18] Pipeline | Issuer/Guarantor | Currency | Size (USD mn) | Tenor | Pricing | Issue Rating (M/S/F) | | --- | --- | --- | --- | --- | --- | | CMBC International Funding (HK) | USD | - | 3yr | SOFR + 115 | -/-/BBB | | New Development Bank | USD | - | 3yr | SOFR MS + 55 | Unrated | [19] News and Market Color - Last Friday, 81 credit bonds were issued onshore with an amount of RMB45bn. In Jan'26, 1,999 credit bonds were issued with a total amount of RMB1,691bn, a 16.2% yoy increase [20] - China is considering selling special government bonds of RMB200bn (cUSD29bn) to recapitalize some insurers and injecting RMB300bn into ICBC and ABC [20] - Macau gaming revenue for Jan'26 rose 24% yoy to MOP22.6bn (cUSD2.8bn) [20] - Indonesia is reforming its equity markets after the Jakarta Composite Index plunged by up to 16.5% [20] - Adani Green's directors plan to seek dismissal in US SEC lawsuit [20] - Azure Power Energy delayed the planned early redemption of AZUPOE 3.575 08/19/26 of USD294.184mn to 13 Feb'26 from 5 Feb'26 [20] - Panama's top court ruled that CK Hutchison's port - operating contract is unconstitutional [20] - China Overseas Grand Oceans priced a 3yr dim sum bond at 3.2%, tightened from IPT at 3.75%, issue size RMB1.3bn [20] - Dalian Wanda announced to redeem USD50mn of DALWAN 11 02/13/28, and the maximum acceptance amount of the tender offer is USD350mn [20] - Muthoot Finance plans to raise USD600mn under the global medium - term note program [20] - Nomura Holdings 9MFY26 net revenue rose 10.5% yoy to JPY1.6tn (cUSD10.4bn) [20] - CTFE is in discussions with potential investors regarding potential investments in NWD, but no agreement has been reached [20] - Vedanta Ltd.'s demerge plan will be effective on 1 Apr'26, and it expects to list four demerged units by mid - May'26 [20] - China Vanke expects its loss attributable to shareholders to widen sharply in FY25 to RMB82bn (cUSD11.8bn) [27] - Yuexiu Property priced a 3yr dim sum bond at 3.4%, tightened from IPT at 3.85%, issue size RMB1.735bn [27]

Group 1: Macro Commentary - The manufacturing PMI in China has shown a decline, indicating weaker demand, with new orders and export orders decreasing [5] - Domestic and external demand weakness is expected to slow growth momentum, prompting potential policy easing before and after the "Two Sessions" [5] - GDP growth is projected to decrease from 5% in 2025 to 4.6% in 2026, with expectations of RRR and LPR cuts [5] Group 2: Industry Commentary - Apple reported FY1Q26 earnings that exceeded expectations, with a 16% year-on-year revenue growth driven by strong iPhone sales and a 38% increase in the Chinese market [5] - The gross margin for Apple improved to 48.2%, and the guidance for FY2Q26 indicates a revenue growth of 13-16% despite supply constraints [5] - The technology sector is expected to benefit from Apple's product cycle and collaborations with Google AI, with companies like Luxshare Precision and BYD Electronics positioned for growth [5] Group 3: Company Commentary - Thermo Fisher reported a strong 4Q25 performance with a 7.2% year-on-year revenue growth, driven by demand from pharmaceutical clients [6] - The company expects a revenue growth of 3.9% to 5.9% for 2026, with adjusted EPS growth of 5.9% to 8.4% [6] - Recent acquisitions are expected to enhance Thermo Fisher's capabilities and drive future growth, with an anticipated adjusted EPS growth of 7-9% [7][8] Group 4: Company Forecasts - Zhengli's battery sales forecast for 2025 has been raised from 18.4 GWh to 19.6 GWh due to strong demand from new electric vehicle models [9] - The average selling price is expected to increase, leading to a projected net profit growth of 550% to 591 million yuan in 2025 [9] - For 2026, Zhengli's sales forecast remains at 30 GWh, with an 8% revenue increase expected, raising the net profit forecast to 1.36 billion yuan [9]

Investment Rating - The report maintains a BUY rating for Thermo Fisher with a new target price of US$670, up from the previous target price of US$654, indicating a potential upside of 15.8% from the current price of US$578.61 [2][8]. Core Insights - Thermo Fisher reported a strong performance in 4Q25, with revenue increasing by 7.2% year-over-year, marking the fastest quarterly growth in 2025. Adjusted EPS rose by 7.7%, surpassing Bloomberg consensus estimates by 2.2% and 1.9%, respectively [1][8]. - The company expects revenue growth of 3.9% to 5.9% and adjusted EPS growth of 5.9% to 8.4% for the full year 2026, reaffirming a long-term organic revenue growth target of 3%-6% [1][8]. Summary by Sections Financial Performance - For FY25, Thermo Fisher's revenue was US$44,556 million, with a year-over-year growth of 3.9%. The adjusted net profit was US$8,643 million, reflecting a growth of 3.1% [9][14]. - The company forecasts revenue of US$46,849 million for FY26, representing a growth of 5.1%, and adjusted net profit of US$9,130 million, which is a 5.6% increase [9][14]. Market Dynamics - The pharmaceutical and biotech sectors were the strongest client segments for Thermo Fisher in 2025, achieving mid-single-digit revenue growth for the year and high-single-digit growth in 4Q25. Management noted increased confidence among pharma companies in their relationships with governments [8]. - Biotech financing showed recovery in the second half of 2025, which is expected to drive revenue growth despite a typical lag of approximately six months between funding and R&D expenditure [8]. Strategic Acquisitions - In 2025, Thermo Fisher completed significant acquisitions, including Solventum's filtration and separation business for US$4.0 billion and Sanofi's sterile fill-finish facility for US$8.9 billion. These acquisitions are anticipated to enhance the company's global leadership in bioproduction and expand its capacity in the U.S. [8][9]. - Management expects adjusted EPS to grow by 7-9% in 2026 as a result of these strategic acquisitions [8]. Service Capabilities - Thermo Fisher's CDMO segment experienced strong growth in 2025, benefiting from limited sterile fill-finish capacity globally. The acquisition of Sanofi's facility is expected to secure growing orders for production in the U.S. [8]. - The integrated Accelerator business aims to improve project execution and reduce time-to-market for innovative drugs, thereby generating significant orders through differentiated service offerings [8].

Investment Rating - The report maintains a BUY rating for Zenergy, with a target price of HK$18.00, indicating a potential upside of 103.4% from the current price of HK$8.85 [3][6]. Core Insights - Zenergy's FY25E net profit forecast has been revised up by 4% to RMB591 million due to a better product mix and expected revenue growth from GAC Toyota, which is anticipated to become the largest revenue contributor [1][6]. - The FY26E net profit forecast has also been increased by 4% to RMB1.36 billion, driven by improved client mix and potential battery price hikes [1][6]. - The company is expected to achieve solid earnings visibility in the second half of FY25, with a projected operating profit of RMB302 million and a net profit of RMB370 million for that period [6][7]. Financial Summary - Revenue projections for FY25E are set at RMB8.2 billion, reflecting a year-on-year growth of 59.8%, while FY26E revenue is expected to reach RMB14.6 billion, a growth of 77.6% [2][10]. - Gross margin is projected to improve from 18.0% in FY25E to 18.5% in FY26E, supported by a better product mix and higher average selling prices [2][8]. - The company is expected to achieve a net profit of RMB1.88 billion by FY27E, with a corresponding EPS of 72.27 RMB cents [2][10]. Earnings Revision - The revenue forecast for FY25E has been increased by 6.9% to RMB8.2 billion, while FY26E revenue has been revised up by 8% to RMB14.6 billion [8][9]. - The net profit estimates for FY25E and FY26E have been adjusted upwards by 3.8% and 3.9% respectively, reflecting the positive outlook for the company's performance [8][9]. Market Performance - Zenergy's market capitalization stands at HK$22.61 billion, with an average turnover of HK$20.2 million over the past three months [4]. - The stock has shown a 7.0% increase over the past month, although it has declined by 13.2% over the past six months [5].

Investment Rating - The report maintains a BUY rating for ServiceNow, indicating a potential return of over 15% over the next 12 months [17]. Core Insights - ServiceNow reported a total revenue increase of 21% YoY to US$3.57 billion in 4Q25, aligning with Bloomberg consensus estimates. Non-GAAP operating income grew by 26% YoY to US$1.10 billion, exceeding consensus by 3% due to AI-enhanced efficiencies and disciplined expense control [1]. - For FY26E, management guided subscription revenue to increase by 20.5%-21% YoY to US$15.53-15.57 billion, with a further 100bps expansion of both non-GAAP operating profit and free cash flow margin to 32% and 36%, respectively, driven by AI-enabled efficiency gains [1]. - The AI product momentum remains strong, with Now Assist annual contract value (ACV) surpassing US$600 million in 4Q25, ahead of the previous target of US$500 million and on track to reach US$1 billion by FY26-end [1]. - The target price for ServiceNow has been lowered to US$215.00 based on a 40x FY26E EV/EBITDA, down from US$236.00 based on a 45x FY26E EV/EBITDA, reflecting sector valuation impacts due to increased competition from AI and LLM service providers [1][12]. Financial Summary - For FY26E, total revenue is projected at US$15.973 billion, with adjusted net profit expected to reach US$4.518 billion, resulting in an adjusted EPS of US$4.36 [2]. - The company’s market capitalization is approximately US$122.22 billion, with a current share price of US$116.73, indicating an upside potential of 84.2% to the target price [3][4]. - The non-GAAP operating profit margin expanded by 1.4 percentage points YoY to 30.9% in 4Q25, attributed to improved efficiency and disciplined expense control [9]. Growth Projections - Subscription revenue is expected to grow by 20.3% in FY26E, with adjusted net profit growth projected at 23.2% [15]. - The company anticipates a revenue growth rate of 20.5%-21% for FY26E, with further growth expected in subsequent years [1][14]. Valuation - The valuation of ServiceNow is set at US$215.00 per share based on a target EV/EBITDA of 40x for FY26E, which is at a premium to the sector average of 29x, justified by the strong earnings growth outlook [12][13].